Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Evogene Ltd. has reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a strategic shift towards its proprietary technology, ChemPass AI™, focusing on small-molecule discovery in the pharmaceutical and agricultural sectors [1][2]. Financial Performance - Revenues for 2025 totaled approximately $3.9 million, down from $5.6 million in 2024, primarily due to lower revenue from AgPlenus and reduced seed sales from Casterra [2][3]. - Operating expenses decreased significantly to approximately $13.8 million in 2025 from $22.0 million in 2024, with fourth-quarter expenses at approximately $3.2 million compared to $4.3 million in the same period of 2024 [2][3]. - The net loss for 2025 was approximately $7.8 million, a decrease from $18.1 million in 2024, attributed to reduced operating expenses and income from discontinued operations [3][4]. Strategic Initiatives - The company has streamlined operations by discontinuing non-core activities and divesting misaligned assets, including the acquisition of Lavie Bio by ICL and the licensing of Biomica's oncology candidate to Lishan Pharmaceuticals [1][2]. - ChemPass AI™ has been advanced through collaborations, including a partnership with Google Cloud, which has enhanced the model's design precision to 90% based on 38 billion structures [1][2]. Market Focus - Evogene is concentrating on two high-impact markets: pharmaceuticals and agriculture, with ChemPass AI™ being utilized for drug discovery and the development of novel herbicides and fungicides [1][2]. - The company aims to maximize the value of its ChemPass AI platform through integrated operations and strategic partnerships, positioning itself for growth in the ag-chemical sector [1][2]. Cash Position - As of December 31, 2025, Evogene held approximately $13.0 million in cash and cash equivalents, with a cash usage of approximately $3.0 million in the fourth quarter [2][3]. - The company expects to sustain reduced expense levels in future periods following its organizational realignment and cost-reduction initiatives [2][3].